Momenta Pharmaceuticals Inc (MNTA)

15.25
0.20 1.30
NASDAQ : Health Care
Prev Close 15.45
Open 15.75
Day Low/High 15.25 / 16.10
52 Wk Low/High 7.86 / 23.62
Volume 637.01K
Avg Volume 724.30K
Exchange NASDAQ
Shares Outstanding 71.85M
Market Cap 1.14B
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving The Board Of Momenta Pharmaceuticals, Inc. -- MNTA

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving The Board Of Momenta Pharmaceuticals, Inc. -- MNTA

Levi & Korsinsky announces it has commenced an investigation of Momenta Pharmaceuticals, Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABMD, ABX, AEM, BGG, BIIB, HBM, HTBI, KALU, MNTA, NEWM, NQ, SNE, VMI, VPG, WMT, XCRA Downgrades: CGNX, DAKT, EXAC, FSLR, HOLI, PFLT Initiations: AGR Read on to get TheStreet Quant Ratings' detailed report:

Analysts' Actions -- Discovery, First Solar, Momenta, VF Corp. and More

Analysts' Actions -- Discovery, First Solar, Momenta, VF Corp. and More

Here are Wednesday's top research calls, including downgrades for Discovery, First Solar and Momenta, and an upgrade for VF Corp.

Sarepta Leads Biotech Movers on Voucher Deal News

Sarepta Leads Biotech Movers on Voucher Deal News

Gilead (finally!) has acquired something from Sarepta, even if it is quite small.

Mylan's Shares Rise Despite FTC Investigation

Mylan's Shares Rise Despite FTC Investigation

The drug company saw its stock climb 3% Tuesday on news that it can move ahead with generic Copaxone.

Premarket Biotech Movers: Mylan, Momenta Pharmaceuticals, Seres Therapeutics

Premarket Biotech Movers: Mylan, Momenta Pharmaceuticals, Seres Therapeutics

Mylan, Momenta Pharmaceuticals and Seres Therapeutics were among the biotech stock movers in premarket trading on Tuesday.

Interesting MNTA Put Options For February 2017

Interesting MNTA Put Options For February 2017

Investors in Momenta Pharmaceuticals Inc saw new options become available this week, for the February 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNTA options chain for the new February 2017 contracts and identified the following put contract of particular interest.

MNTA Crosses Above Average Analyst Target

MNTA Crosses Above Average Analyst Target

In recent trading, shares of Momenta Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $15.50, changing hands for $15.70/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Medtronic, Patterson Among Day's Biggest Losers, Trump Continues to Pressure Healthcare Sector

Medtronic, Patterson Among Day's Biggest Losers, Trump Continues to Pressure Healthcare Sector

President-elect Trump's vague healthcare policy has put the $3 trillion industry on edge.

Momenta Pharmaceuticals Announces Publication On The Design Of M230, A Novel Autoimmune Disease Drug Candidate, In Science Translational Medicine

Momenta Pharmaceuticals Announces Publication On The Design Of M230, A Novel Autoimmune Disease Drug Candidate, In Science Translational Medicine

Data show M230's ability to block immune complex-mediated damage and robust efficacy in preclinical

Momenta And Mylan Initiate Phase 1 Clinical Trial For M834, A Proposed Biosimilar Of ORENCIA® (abatacept)

Momenta And Mylan Initiate Phase 1 Clinical Trial For M834, A Proposed Biosimilar Of ORENCIA® (abatacept)

-- Advancement of M834 to clinical-stage development represents important milestone in the Momenta/Mylan biosimilar portfolio --

Momenta And Mylan Initiate Phase 1 Clinical Trial For M834, A Proposed Biosimilar Of ORENCIA® (abatacept)

Momenta And Mylan Initiate Phase 1 Clinical Trial For M834, A Proposed Biosimilar Of ORENCIA® (abatacept)

Advancement of M834 to clinical-stage development represents important milestone in the Momenta/Mylan biosimilar portfolio